SDGR

AI MemoPost-earnings T+1

Schrodinger

As of 2026-08-06/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 ACV growth and Bunsen early access • 2026-08-05

Expected move: +1%

Biggest risk

The evidence does not establish a consensus beat, improved guidance, or durable Bunsen monetization. The deterministic prior remains negative, and the lack of analyst revisions or confirmed market-reaction attribution limits conviction.

Invalidation

Break below $14 or thesis failure.

What would change my mind?

Q2 ACV growth of 27% and the Bunsen launch provide a credible platform-adoption signal. A sustained conversion of early access into paid usage could support reacceleration and multiple expansion. [#SEC-8K-2026-08-05]

Research note

Recommendation

—

Confidence

medium

As of

2026-08-06

Base target

$18

p=1%

Bull target

$23

p=0%

Bear target

$14

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

T+1 post-earnings re-rating risk
Bunsen adoption and recurring ACV conversion
Q2 ACV growth of 27% and the Bunsen launch provide a credible platform-adoption signal.

BearKey bullets

Bunsen early access may not convert into durable paid deployments or incremental ACV.
Consensus revenue/EPS surprise, guidance revisions, analyst target changes, and estimate revisions were unavailable in the packet.
Forward visibility remains limited despite the positive ACV disclosure; avoid assuming earnings durability from one quarter.

WatchKey bullets

Q2 ACV growth and Bunsen early access

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $18 (p=1%)

Bull/Bear spread: +29% / -24%

Vs latest close: Bull +29% · Base +1% · Bear -24%

Scenario probabilities

Bull Target: $23 (p=0%)Base Target: $18 (p=1%)Bear Target: $14 (p=0%)

Commentary

T+1 post-earnings follow-up. Company-source evidence is constructive on ACV growth and Bunsen, while consensus surprise, analyst revisions, target changes, and confirmed post-print price reaction remain unavailable. Recent headline activity is high, but social coverage and options data were absent; the result is a cautious monitoring view rather than a strong directional thesis.

As of 2026-08-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

T+1 post-earnings re-rating risk
Bunsen adoption and recurring ACV conversion

Scenarios

Bull Target (Scenario probability)

$23 / p=0% prob

Base Target (Scenario probability)

$18 / p=1% prob

Bear Target (Scenario probability)

$14 / p=0% prob

Price $18 as of 2026-08-06

Nearest Scenario: Base (∆ 1%)

Targets vs latest close: Bull +29% · Base +1% · Bear -24%

Sentiment & Exposure

News Sentiment (30d)

0.60

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-05
Q2 ACV growth and Bunsen early access
The company reported Q2 ACV of $29.6 million, up 27%, and launched an early-access version of Bunsen, its agentic AI co-scientist for molecular discovery. This is constructive, but revenue/EPS surprise versus consensus and detailed guidance changes were not available. [#SEC-8K-2026-08-05]
Prob 65.00% • Move 8.00% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

T+1 post-earnings re-rating risk
2026-11-04
Near-term volatility remains elevated while investors digest the print. No confirmed analyst target changes, estimate revisions, consensus surprise, or post-release price-reaction attribution was available, leaving downside risk if expectations were higher than the disclosed operating signal.
Prob 55% • Move -5% • Priced-in 35%

Long-term Catalysts

Months to a year

Bunsen adoption and recurring ACV conversion
2027-08-06
If early-access usage converts into broader paid deployments and expands recurring software ACV, Bunsen could strengthen Schrödinger’s platform-adoption narrative. This remains an execution and monetization hypothesis rather than confirmed forward guidance. [#SEC-8K-2026-08-05]
Prob 45% • Move 25% • Priced-in 20%

Risks

Bunsen early access may not convert into durable paid deployments or incremental ACV.
Consensus revenue/EPS surprise, guidance revisions, analyst target changes, and estimate revisions were unavailable in the packet.
Forward visibility remains limited despite the positive ACV disclosure; avoid assuming earnings durability from one quarter.
The CEO reported open-market sales in April 2026; this is an insider-sentiment signal only and not evidence about operating performance. [#SEC-FORM4-2026-04-17]

Peers

Symbol	Summary
CERT	Closest supplied candidate by life-sciences software adjacency, but still a loose comp; no peer operating or valuation metrics were supplied.
BSX	Useful only as a broad healthcare reference; its large medical-device business has limited business-model read-through to SDGR.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-06

AI Stock Memo: SDGR - Schrodinger - RankAlpha